Dr. Chang Ahn Announces Phase IIa Study Results of Serdaxin in Major Depressive Disorder
CONTACTS:
Stephanie Ascher
Stern Investor Relations, Inc.
212-362-1200
stephanie@sternir.com
Constantine Theodoropulos
Base Pair Communications
617-401-3116
constantine@basepaircomm.com
Stephanie Ascher
Stern Investor Relations, Inc.
212-362-1200
stephanie@sternir.com
Constantine Theodoropulos
Base Pair Communications
617-401-3116
constantine@basepaircomm.com
Recent Press Releases
- Rexahn Pharmaceuticals Submits Archexin Phase II Protocol for Ovarian Cancer to FDA
May 8th, 2012 - Rexahn Pharmaceuticals Issued Japanese Patent for New Anti-cancer Compounds
April 30th, 2012 - Rexahn Pharmaceuticals to Present Data on Novel Anti-Cancer Small Molecule RX-3117 at AACR 103rd Annual Meeting
March 27th, 2012 - Rexahn Pharmaceuticals Enrolls First Subject in Exploratory Phase I Clinical Study of RX-3117
March 13th, 2012 - Rexahn Pharmaceuticals Secures Approval in Europe to Conduct a First-in-Human Trial of RX-3117 in Solid Tumors
January 18th, 2012
Contacts
Stern Investor Relations, Inc.Stephanie Ascher
212-362-1200
stephanie@sternir.com
BasePair Communications
Constantine Theodoropulos
617-816-4637
constantine@basepaircomm.com
